ProfileGDS5678 / 1428131_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 89% 91% 90% 91% 90% 91% 90% 89% 89% 90% 88% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.0985890
GSM967853U87-EV human glioblastoma xenograft - Control 27.3158690
GSM967854U87-EV human glioblastoma xenograft - Control 37.0480489
GSM967855U87-EV human glioblastoma xenograft - Control 47.6371391
GSM967856U87-EV human glioblastoma xenograft - Control 57.3806690
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1033991
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9847890
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.4356591
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.248190
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.0617789
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.929989
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2215790
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.879488
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3928691